Kamran Ahmed, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the interim results of a prospective, non-randomized, open-label Phase II study (NCT03614949) investigating the use of atezolizumab alongside stereotactic body radiation therapy (SBRT) in patients with metastatic, recurrent, or persistent cervical cancer. The median progression-free survival (PFS) rate was 4.5 months, while the median overall survival (OS) rate was 11 months. The 6-month OS rate was 84%. Of the 13 patients included in the interim analysis, 2 patients had objective responses. Dr Ahmed highlights that these results meet the pre-determined criteria to allow the study to progress to its second stage. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
